PerkinElmer subsidiary Euroimmun has received CE marks for two COVID-19 assays — the Anti-SARS-CoV-2 Omicron ELISA (IgG) and Anti-SARS-CoV-2 RBD ChLIA (IgG) tests.

The Anti-SARS-CoV-2 Omicron ELISA (IgG) test is an enzyme-linked immunosorbent assay that targets the spike protein of the SARS-CoV-2 Omicron variant and can quantify IgG antibodies formed against the variant.

Anti-SARS-CoV-2 RBD ChLIA (IgG) is a chemiluminescent immunoassay that also measures IgG antibodies against the virus.

Both test systems are now available to laboratories in countries that accept the CE mark, the company said.